- The stock price of Femasys Inc (NASDAQ: FEMY) increased by over 35% during intraday trading. This is why it happened.
The stock price of Femasys Inc (NASDAQ: FEMY) – a biomedical company focused on transforming women’s healthcare – increased by over 35% during intraday trading. Investors are responding positively to Femasys announcing the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first-in-class and localized directional insemination product candidate for infertility.
The LOCAL trial is going to be conducted across approximately 20 centers in the United States and is expected to enroll up to 792 patients diagnosed as infertile. And the primary endpoints of the study are to determine the effectiveness (clinical pregnancy rate) and safety over a period of 7 weeks.
“For more than 20 years, current approaches to infertility treatment have been limited during the initial stage of therapeutic care, but with the advancement of FemaSeed, we believe a next generation intrauterine procedure may have the opportunity to truly change this traditional paradigm. The LOCAL trial is the next step in proving the FemaSeed localized directional insemination approach. My colleagues and I are thrilled to be a part of this patient care evolution.”
— Michael Glassner, MD, Founding Partner and Medical Director of Main Line Fertility & Reproductive Medicine in Pennsylvania, where the first patient in the LOCAL trial was treated in July 2021
“Infertility has become a global issue and the commencement of the LOCAL trial underscores our commitment to ensure that women struggling to become pregnant receive the best, lowest cost treatment option by developing our innovative directional delivery platform technology.”
— Kathy Lee-Sepsick, founder, President & Chief Executive Officer of Femasys
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.